ozempic and retatrutide changed the conversation. Now obesity medicine experts are watching what could come next: Retatrutide. In this episode of unPAUSED, Dr. Michelle Gordon breaks down why researchers are so excited about this Retatrutide: What It Is &
Description
It cannot cover an 8mg or 12mg dose because the vial holds only 5mg total
A position, not a slogan GLP-1 receptor agonists are neither the answer nor the problem
This is especially important if youre taking other blood sugar medications
Ongoing Research on Combination Therapies Empagliflozin's role in combination therapies continues to be a significant area of research
Both trials demonstrated dose-dependent efficacy that appeared competitive with injectable GLP-1 agonists (see our drug comparison hub), a finding that electrified the pharmaceutical industry and investor community
